Production (Stage)
The Oncology Institute, Inc.
TOI
$3.02
$0.031.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 4.13% | 0.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.13% | 0.37% | |||
| Cost of Revenue | 1.78% | 0.11% | |||
| Gross Profit | 17.85% | 1.88% | |||
| SG&A Expenses | 2.08% | -6.71% | |||
| Depreciation & Amortization | 4.51% | 8.52% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.89% | -1.37% | |||
| Operating Income | 16.92% | 13.89% | |||
| Income Before Tax | -48.57% | 18.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -48.57% | 18.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -48.57% | 18.19% | |||
| EBIT | 16.92% | 13.89% | |||
| EBITDA | 20.50% | 16.76% | |||
| EPS Basic | -77.50% | 18.28% | |||
| Normalized Basic EPS | -16.55% | 15.81% | |||
| EPS Diluted | -73.14% | 18.50% | |||
| Normalized Diluted EPS | -16.55% | 15.81% | |||
| Average Basic Shares Outstanding | 1.91% | 0.17% | |||
| Average Diluted Shares Outstanding | 1.91% | 0.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||